FONT-SIZE Plus   Neg

Hasbro Q2 Profit Misses View - Quick Facts

Toy maker Hasbro Inc. (HAS) posted lower second-quarter reported net earnings of $36.48 million, or $0.28 per share, compared with $43.43 million, or $0.33 per share a year back.

Excluding pre-tax partial pension settlement charges of $2.5 million, or $0.01 per share, associated with previously disclosed restructuring actions, adjusted net earnings for the period were $38.3 million, or $0.29 per share. On average, 13 analysts polled by Thomson Reuters expected earnings per share of $0.34 for the quarter. Analysts' estimates typically exclude one-time items.

During the recent quarter, the firm clocked $766.3 million in net revenues, down 6% from last year's $811.5 million, whereas 11 analysts estimated revenues of $794.71 million for the quarter.

As announced earlier, the firm is undertaking a cost savings initiative designed to better align resources and costs while targeting $100 million in annual savings by 2015. The gross savings expectation for 2013 continues to be $45 million - $48 million, resulting in expected net savings of $13 million - $15 million for the year, prior to pension charges.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Visa Inc. (V) on Monday reported an increase in profit for the fourth quarter, as revenues jumped driven largely by increase in customer spending and inclusion of Europe business. Earnings and revenues trumped Wall Street expectations. Foster City, California-based Visa's fourth-quarter profit rose... As Sony Corp. prepares to launch the new PlayStation 4 Pro gaming console on November 10, several new games that are compatible with the console have also been confirmed for launch. Game developers are readying to provide PlayStation 4 Pro support for many games on PS4. Shares of Advaxis Inc. dropped more than 13 percent in pre-market activity before paring losses to just more than 5 percent after the company said that it was not able to complete the second stage of the Phase 2 GOG-0265 trial as designed due to a clinical hold that affected its clinical development programs last year.
comments powered by Disqus
Follow RTT